Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework

5 Jul 2023

Abstract excerpt

Optimal pharmacokinetic (PK) properties of therapeutic monoclonal antibodies (mAbs) are essential to achieve the desired pharmacological benefits in patients. To accomplish this, we followed an approach comprising structure-based mAb charge engineering in conjunction with the use of relevant preclinical models to screen and select humanized candidates with PK suitable for clinical development. Murine mAb...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Protein purification and stability
Share to Receptor Mechanisms and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37408314
DOI: 10.1080/19420862.2023.2232087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human frameworkPMID 37408314Read ↗

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodiesSemantic proximity Read ↗

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodiesSemantic proximity Read ↗

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domainSemantic proximity Read ↗

Electrostatic interactions modulate the differential aggregation propensities of IgG1 and IgG4P antibodies and inform charged residue substitutions for improved developabilitySemantic proximity Read ↗

An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.Semantic proximity Read ↗

A novel antibody humanization method based on epitopes scanning and molecular dynamics simulation.Semantic proximity Read ↗

Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies.Semantic proximity Read ↗

Charge variants in IgG1Semantic proximity Read ↗

Should charge variants of monoclonal antibody therapeutics be considered critical quality attributes?Semantic proximity Read ↗

Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point.Semantic proximity Read ↗

Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.Semantic proximity Read ↗

The Therapeutic Antibody Profiler (TAP): Five Computational Developability GuidelinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.